PE20152001A1 - Arilquinazolinas - Google Patents
ArilquinazolinasInfo
- Publication number
- PE20152001A1 PE20152001A1 PE2015002381A PE2015002381A PE20152001A1 PE 20152001 A1 PE20152001 A1 PE 20152001A1 PE 2015002381 A PE2015002381 A PE 2015002381A PE 2015002381 A PE2015002381 A PE 2015002381A PE 20152001 A1 PE20152001 A1 PE 20152001A1
- Authority
- PE
- Peru
- Prior art keywords
- phenyl
- pyridazin
- morpholin
- halo
- methanol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C25/00—Compounds containing at least one halogen atom bound to a six-membered aromatic ring
- C07C25/02—Monocyclic aromatic halogenated hydrocarbons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Closures For Containers (AREA)
Abstract
La invencion se refiere a nuevos compuestos de la formula (I), que se pueden usar para la inhibicion de serina treonina proteina quinasas, asi como para la sensibilizacion de celulas cancerosas ante agentes anticancer y/o radiacion ionizante. Donde X es CH, CF, S o N, Y es CH, S o N, Z es C o N, --- Forma, cuando Z=C, junto con el enlace simple un enlace doble. Esta ausente cuando Z=N. n ES 1 o 2 en donde cuando N=1, X=S. y cuando n=2, ambos son X=CH, etc. R1, R2, R3, R4 son H, halo, etc. R5 es H, halo, etc. C y C es fenilo no sustituido o mono sustituido o disustituido por R6, etc. R6 es halo, etc. Compuestos preferidos son: [2-cloro-4-fluoro-5-(7-morfolin-4-il-quinazolin-4-il)-fenil]-(5-metoxi-piridazin-3-il)-metanol, [4-fluoro-3-(7-morfolin-4-il-quinazolin-4-il)-fenil]-(5-metoxi-piridazin-3-il)-metanol, [2,4-difluoro-5-[7-morfolin-4-il-quinazol-4-il)-fenil]-imidazol[1,2-b]piridazin-6-il-metanol
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102013008118.1A DE102013008118A1 (de) | 2013-05-11 | 2013-05-11 | Arylchinazoline |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20152001A1 true PE20152001A1 (es) | 2016-01-13 |
Family
ID=50729442
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2015002381A PE20152001A1 (es) | 2013-05-11 | 2014-05-08 | Arilquinazolinas |
Country Status (32)
Country | Link |
---|---|
US (5) | US9732094B2 (es) |
EP (1) | EP2994467B1 (es) |
JP (1) | JP6562903B2 (es) |
KR (1) | KR102292811B1 (es) |
CN (1) | CN105358552B (es) |
AR (2) | AR096235A1 (es) |
AU (1) | AU2014267723B2 (es) |
BR (1) | BR112015027951B1 (es) |
CA (1) | CA2911668C (es) |
CL (1) | CL2015003285A1 (es) |
DE (1) | DE102013008118A1 (es) |
DK (1) | DK2994467T3 (es) |
ES (1) | ES2693774T3 (es) |
HK (1) | HK1221719A1 (es) |
HR (1) | HRP20181775T1 (es) |
HU (1) | HUE041397T2 (es) |
IL (2) | IL242348B (es) |
LT (1) | LT2994467T (es) |
MX (1) | MX362183B (es) |
MY (1) | MY173126A (es) |
NZ (1) | NZ713362A (es) |
PE (1) | PE20152001A1 (es) |
PH (1) | PH12015502339A1 (es) |
PL (1) | PL2994467T3 (es) |
PT (1) | PT2994467T (es) |
RS (1) | RS57838B1 (es) |
RU (1) | RU2701193C2 (es) |
SG (1) | SG11201509268YA (es) |
SI (1) | SI2994467T1 (es) |
TR (1) | TR201816069T4 (es) |
UA (1) | UA116020C2 (es) |
WO (1) | WO2014183850A1 (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102013008118A1 (de) | 2013-05-11 | 2014-11-13 | Merck Patent Gmbh | Arylchinazoline |
CN112263677A (zh) | 2015-02-26 | 2021-01-26 | 默克专利股份公司 | 用于治疗癌症的pd-1/pd-l1抑制剂 |
IL256245B (en) | 2015-06-16 | 2022-09-01 | Merck Patent Gmbh | Treatments that combine a pd-l1 antagonist |
WO2017166104A1 (en) * | 2016-03-30 | 2017-10-05 | Merck Sharp & Dohme Corp. | Purine inhibitors of human phosphatidylinositol 3-kinase delta |
WO2018065938A1 (en) | 2016-10-06 | 2018-04-12 | Pfizer Inc. | Dosing regimen of avelumab for the treatment of cancer |
EP3554495A1 (en) * | 2016-12-19 | 2019-10-23 | Merck Patent GmbH | Combination of a protein kinase inhibitor and an additional chemotherapeutic agent |
CA3058280C (en) * | 2017-03-30 | 2023-11-28 | Merck Patent Gmbh | Crystalline form of (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)-methanol |
JP7166278B2 (ja) * | 2017-03-30 | 2022-11-07 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | がんの治療のための抗pd-l1抗体およびdna-pkインヒビターの併用 |
IL269667B2 (en) | 2017-03-30 | 2024-09-01 | Merck Patent Gmbh | Solid forms of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol, their preparation and medicinal preparations containing them |
PL3601277T3 (pl) | 2017-03-30 | 2024-07-08 | Merck Patent Gmbh | Preparat farmaceutyczny |
IL276080B2 (en) * | 2018-01-17 | 2023-10-01 | Vertex Pharma | DNA-PK suppressor compounds, UTP-containing preparations and their uses |
CA3099079A1 (en) | 2018-05-04 | 2019-11-07 | Merck Patent Gmbh | Combined inhibition of pd-1/pd-l1, tgf.beta. and dna-pk for the treatment of cancer |
WO2020068600A1 (en) * | 2018-09-24 | 2020-04-02 | Rapt Therapeutics, Inc. | Ubiquitin-specific-processing protease 7 (usp7) modulators and uses thereof |
US20220154220A1 (en) | 2018-12-21 | 2022-05-19 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Small molecules for increasing precise genome editing efficiency |
CN111909144A (zh) * | 2019-05-10 | 2020-11-10 | 山东轩竹医药科技有限公司 | 喹唑啉类dna-pk抑制剂 |
US20220267310A1 (en) * | 2019-06-27 | 2022-08-25 | Medshine Discovery Inc. | Quinazoline and cinnoline derivatives as dna-pk inhibitor |
CN112300132A (zh) * | 2019-07-30 | 2021-02-02 | 山东轩竹医药科技有限公司 | 芳基喹唑啉类dna-pk抑制剂 |
WO2022058323A1 (en) | 2020-09-18 | 2022-03-24 | Merck Patent Gmbh | Compounds for the treatment of viral infections |
JP2023546159A (ja) * | 2020-10-19 | 2023-11-01 | バルーク エス.ブルームバーグ インスティテュート | がんを診断および治療するための方法およびキット |
TW202229281A (zh) * | 2020-12-24 | 2022-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 嘌呤酮類化合物、其製備方法及其在醫藥上的應用 |
WO2022143671A1 (zh) * | 2020-12-28 | 2022-07-07 | 南京明德新药研发有限公司 | 吗啉取代的苯并嘧啶类化合物的晶型及其制备方法 |
US20240300977A1 (en) | 2021-04-17 | 2024-09-12 | Intellia Therapeutics, Inc. | Inhibitors of dna-dependent protein kinase and compositions and uses thereof |
CN115557900B (zh) * | 2022-11-11 | 2024-03-15 | 常州大学 | 一种3-取代哒嗪衍生物的合成方法 |
WO2024104822A1 (en) | 2022-11-16 | 2024-05-23 | Basf Se | Substituted tetrahydrobenzodiazepine as fungicides |
WO2024104815A1 (en) | 2022-11-16 | 2024-05-23 | Basf Se | Substituted benzodiazepines as fungicides |
WO2024104818A1 (en) | 2022-11-16 | 2024-05-23 | Basf Se | Substituted benzodiazepines as fungicides |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SK400992A3 (en) | 1990-11-06 | 1995-08-09 | Pfizer | Quinazolines derivatives for enhancing antitumor activity |
CN1169527A (zh) * | 1996-06-24 | 1998-01-07 | 考克库姆·索尼克斯公司 | 低频声的声发射器 |
AR012634A1 (es) * | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
UA71555C2 (en) * | 1997-10-06 | 2004-12-15 | Zentaris Gmbh | Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives |
EP1187633A4 (en) | 1999-04-08 | 2005-05-11 | Arch Dev Corp | USE OF ANTI-VEGF ANTIBODY FOR INCREASING IRRADIATION IN CANCER THERAPY |
US7276519B2 (en) | 2002-11-25 | 2007-10-02 | Wyeth | Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors |
GB0423653D0 (en) * | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
JP2009534454A (ja) * | 2006-04-25 | 2009-09-24 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
AR060632A1 (es) * | 2006-04-26 | 2008-07-02 | Genentech Inc | Compuestos inhibidores de fosfoinositida 3- quinasa y metodos de uso |
JP5227321B2 (ja) * | 2006-08-23 | 2013-07-03 | クドス ファーマシューティカルズ リミテッド | Mtor阻害剤としての2−メチルモルホリンピリド−、ピラゾ−及びピリミド−ピリミジン誘導体 |
KR101507182B1 (ko) * | 2006-12-07 | 2015-03-30 | 제넨테크, 인크. | 포스포이노시타이드 3-키나제 억제제 화합물 및 그의 사용 방법 |
JP2011502141A (ja) * | 2007-10-29 | 2011-01-20 | ナトコ ファーマ リミテッド | 抗癌剤としての4‐(テトラゾール‐5‐イル)‐キナゾリン誘導体 |
JP2011524917A (ja) | 2008-06-20 | 2011-09-08 | メタボレックス, インコーポレイテッド | アリールgpr119作動薬およびその使用 |
WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
WO2010075273A1 (en) | 2008-12-23 | 2010-07-01 | Schering Corporation | Bicyclic heterocycle derivatives and methods of use thereof |
NZ595747A (en) * | 2009-03-18 | 2015-06-26 | Resverlogix Corp | Novel quinazolinones and related compounds for use as anti-inflammatory agents |
JP2012520887A (ja) | 2009-03-18 | 2012-09-10 | シェーリング コーポレイション | ジアシルグリセロールアシルトランスフェラーゼの阻害剤としての二環式化合物 |
JP2013522249A (ja) * | 2010-03-16 | 2013-06-13 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | モルホリニルキナゾリン |
WO2012016133A2 (en) | 2010-07-29 | 2012-02-02 | President And Fellows Of Harvard College | Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers |
EP2603490A4 (en) | 2010-08-10 | 2014-01-01 | Abbvie Inc | NEW TRPV3 MODULATORS |
US20120184572A1 (en) | 2011-01-13 | 2012-07-19 | Metabolex, Inc. | Aryl gpr119 agonists and uses thereof |
DE102011118830A1 (de) | 2011-11-18 | 2013-05-23 | Merck Patent Gmbh | Morpholinylbenzotriazine |
US9013997B2 (en) | 2012-06-01 | 2015-04-21 | Broadcom Corporation | System for performing distributed data cut-through |
JP6318156B2 (ja) | 2012-09-06 | 2018-04-25 | プレキシコン インコーポレーテッドPlexxikon Inc. | キナーゼをモジュレートするための化合物および方法、ならびにその指標 |
DE102013008118A1 (de) | 2013-05-11 | 2014-11-13 | Merck Patent Gmbh | Arylchinazoline |
AU2014295000A1 (en) | 2013-07-25 | 2016-02-18 | Fondazione Telethon | Inhibitors of FAPP2 and uses thereof |
EP3554495A1 (en) * | 2016-12-19 | 2019-10-23 | Merck Patent GmbH | Combination of a protein kinase inhibitor and an additional chemotherapeutic agent |
CA3058280C (en) * | 2017-03-30 | 2023-11-28 | Merck Patent Gmbh | Crystalline form of (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)-methanol |
PL3601277T3 (pl) * | 2017-03-30 | 2024-07-08 | Merck Patent Gmbh | Preparat farmaceutyczny |
IL269667B2 (en) * | 2017-03-30 | 2024-09-01 | Merck Patent Gmbh | Solid forms of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol, their preparation and medicinal preparations containing them |
-
2013
- 2013-05-11 DE DE102013008118.1A patent/DE102013008118A1/de not_active Withdrawn
-
2014
- 2014-05-08 US US14/890,214 patent/US9732094B2/en active Active
- 2014-05-08 WO PCT/EP2014/001236 patent/WO2014183850A1/de active Application Filing
- 2014-05-08 PT PT14726074T patent/PT2994467T/pt unknown
- 2014-05-08 AU AU2014267723A patent/AU2014267723B2/en active Active
- 2014-05-08 CN CN201480039487.2A patent/CN105358552B/zh active Active
- 2014-05-08 BR BR112015027951-1A patent/BR112015027951B1/pt active IP Right Grant
- 2014-05-08 EP EP14726074.9A patent/EP2994467B1/de active Active
- 2014-05-08 ES ES14726074.9T patent/ES2693774T3/es active Active
- 2014-05-08 MY MYPI2015704014A patent/MY173126A/en unknown
- 2014-05-08 UA UAA201512039A patent/UA116020C2/uk unknown
- 2014-05-08 RU RU2015153094A patent/RU2701193C2/ru active
- 2014-05-08 HU HUE14726074A patent/HUE041397T2/hu unknown
- 2014-05-08 PL PL14726074T patent/PL2994467T3/pl unknown
- 2014-05-08 JP JP2016512249A patent/JP6562903B2/ja active Active
- 2014-05-08 SG SG11201509268YA patent/SG11201509268YA/en unknown
- 2014-05-08 MX MX2015015512A patent/MX362183B/es active IP Right Grant
- 2014-05-08 DK DK14726074.9T patent/DK2994467T3/en active
- 2014-05-08 PE PE2015002381A patent/PE20152001A1/es active IP Right Grant
- 2014-05-08 KR KR1020157035134A patent/KR102292811B1/ko active IP Right Grant
- 2014-05-08 RS RS20181292A patent/RS57838B1/sr unknown
- 2014-05-08 LT LTEP14726074.9T patent/LT2994467T/lt unknown
- 2014-05-08 SI SI201430943T patent/SI2994467T1/sl unknown
- 2014-05-08 TR TR2018/16069T patent/TR201816069T4/tr unknown
- 2014-05-08 CA CA2911668A patent/CA2911668C/en active Active
- 2014-05-08 NZ NZ713362A patent/NZ713362A/en unknown
- 2014-05-09 AR ARP140101881A patent/AR096235A1/es active IP Right Grant
-
2015
- 2015-10-08 PH PH12015502339A patent/PH12015502339A1/en unknown
- 2015-10-29 IL IL242348A patent/IL242348B/en unknown
- 2015-11-09 CL CL2015003285A patent/CL2015003285A1/es unknown
-
2016
- 2016-08-19 HK HK16109930.6A patent/HK1221719A1/zh unknown
-
2017
- 2017-06-26 US US15/633,064 patent/US10172859B2/en active Active
-
2018
- 2018-10-29 HR HRP20181775TT patent/HRP20181775T1/hr unknown
- 2018-11-13 US US16/189,113 patent/US10383874B2/en active Active
-
2019
- 2019-06-26 US US16/452,604 patent/US11065253B2/en active Active
-
2021
- 2021-05-28 US US17/303,403 patent/US20220117970A1/en not_active Abandoned
- 2021-08-04 IL IL285390A patent/IL285390A/en unknown
-
2022
- 2022-01-12 AR ARP220100052A patent/AR124607A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20152001A1 (es) | Arilquinazolinas | |
PE20160546A1 (es) | Compuestos derivados de piridilo biciclicos fusionados a anillo como inhibidores de fgfr4 | |
CL2018001791A1 (es) | Procesos e intermedios para hacer un inhibidor de jak (divisional solicitud 2468-2015). | |
CR20180367A (es) | Compuestos útiles como inhibidores de cinasa | |
MA42109A (fr) | Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase | |
CU20150053A7 (es) | Inhibidores de bmi-1 de pirimidina inversa sustituida | |
PH12015501934B1 (en) | New octahydro - pyrrolo [3,4-c] - pyrrole derivatives and analogs thereof as autotaxin inhibitors | |
CL2018000786A1 (es) | Nuevos derivados de pirrolo[2,3-d]pirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen. | |
GT201500196A (es) | Derivados de 1 - (benzoilo- sustituido) - 5 - fluoro - 4 - imino - 3 - metil - 3, 4 - dihidropirimidin- 2 (1h) - ona | |
EA201390633A1 (ru) | Новые вещества для повторно перерабатываемых эпоксидных смол | |
CR20150661A (es) | Compuestos de n-(tetrazol-5-il)- y n-(triazol-5-il)arilcarboxamida sustituidos y su uso como herbicidas | |
MA38982A1 (fr) | Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl | |
ECSP11010880A (es) | Compuestos orgánicos | |
CL2017002856A1 (es) | Compuestos de tioéter como inhibidores de la nitrificación | |
MX2014002208A (es) | Inhibidores de serina/treonina quinasa. | |
ECSP15032859A (es) | Derivados de n-(sustituido)-5-fluoro-4-imino-3-metil-2-oxo-3,4-dihidropirimidin-1(2h)-carboxilato | |
CR20160070A (es) | Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos | |
AR097253A1 (es) | Derivado de pirazolilpirazol sustituido y el uso del mismo como herbicida | |
BR112014030474A2 (pt) | novos compostos bicíclicos de tiofenilamida | |
CL2020002217A1 (es) | Uso de alcoxipirazoles como inhibidores de la nitrificación | |
BR112015026055A2 (pt) | novos compostos de pirimidina condensados substituídos | |
EA201300611A1 (ru) | Меченныелютецием аналоги бомбезина для лучевой терапии | |
CR20150148A (es) | Azaindolinas | |
EA201690818A1 (ru) | Замещенные пиримидиновые соединения и их применение в качестве syk ингибиторов | |
CY1118552T1 (el) | Νεα παραγωγα πυριμιδινης ως αναστολεις φωσφοδιεστερασης 10 (pde-10) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |